ValuEngine cut shares of FibroGen (NASDAQ:FGEN) from a hold rating to a sell rating in a research report released on Friday morning.

Other equities research analysts also recently issued reports about the company. Leerink Swann reaffirmed an outperform rating and set a $82.00 price objective (up from $52.00) on shares of FibroGen in a report on Tuesday, August 8th. William Blair reaffirmed an outperform rating on shares of FibroGen in a report on Wednesday, August 9th. Citigroup lifted their price objective on FibroGen from $48.00 to $65.00 and gave the company a top pick rating in a report on Tuesday, August 8th. Jefferies Group reaffirmed a buy rating and set a $75.00 price objective on shares of FibroGen in a report on Tuesday, August 8th. Finally, Stifel Nicolaus lifted their price objective on FibroGen from $38.00 to $80.00 and gave the company a buy rating in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $65.67.

Shares of FibroGen (NASDAQ:FGEN) opened at $44.50 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen has a 1-year low of $19.25 and a 1-year high of $60.15.

In other news, Director Thomas F. Kearns, Jr. sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $45.22, for a total value of $813,960.00. Following the transaction, the director now directly owns 156,564 shares of the company’s stock, valued at approximately $7,079,824.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Pat Cotroneo sold 2,851 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $49.45, for a total value of $140,981.95. Following the completion of the transaction, the vice president now directly owns 157,405 shares in the company, valued at $7,783,677.25. The disclosure for this sale can be found here. Insiders sold a total of 399,982 shares of company stock worth $21,250,362 over the last three months. 13.60% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Parametric Portfolio Associates LLC acquired a new position in FibroGen during the 1st quarter worth $249,000. Schwab Charles Investment Management Inc. lifted its holdings in FibroGen by 16.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 236,373 shares of the biopharmaceutical company’s stock worth $5,827,000 after buying an additional 33,840 shares in the last quarter. Bank of America Corp DE lifted its holdings in FibroGen by 2.4% during the 1st quarter. Bank of America Corp DE now owns 103,522 shares of the biopharmaceutical company’s stock worth $2,552,000 after buying an additional 2,469 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in FibroGen by 71.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 57,502 shares of the biopharmaceutical company’s stock worth $1,857,000 after buying an additional 23,875 shares in the last quarter. Finally, Strs Ohio lifted its holdings in FibroGen by 1.6% during the 2nd quarter. Strs Ohio now owns 143,000 shares of the biopharmaceutical company’s stock worth $4,618,000 after buying an additional 2,300 shares in the last quarter. 57.42% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “FibroGen (FGEN) Cut to Sell at ValuEngine” was posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/fibrogen-fgen-cut-to-sell-at-valuengine/1745082.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.